CoPilot: Disease Management/Reducing Payer Cost

Improving MS Adherence, ISPOR



LEVERAGING DISEASE MANAGEMENT & TECHNOLOGY TO HELP MULTIPLE SCLEROSIS PATIENTS ADHERE TO TREATMENT PLAN

Charles A. Stevens, JD, MBA, CoPilot Provider Services | Bincy Varghese, PharmD, CareMed Specialty Pharmacy Moby Kazmi, MD, CoPilot Provider Services | Gabe Tochterman, BS, CoPilot Provider Services

Objectives

Determine if patients who enroll in a CareMed Specialty Pharmacy and CoPilot Provider Services led disease management program for the treatment of Multiple Sclerosis (MS) with SC/IM therapy are more adherent than patients who are not enrolled in such a support program. Recent MS study results show that adherence of patients on SC/IM therapy is 70.8%; these patients were not supported by any disease management programs. Further, MS patients who took their medication consistently were found to have 66% fewer emergency room (ER) visits and 23% lower medical costs than those MS patients who did not. Average MS-related medical costs for patients in the lowest medication adherence range were \$23,253, while those in the highest adherence range averaged \$17,814, resulting in an average savings over \$5,400.

Methods

- Enroll 1,647 patients in a disease management program and track their adherence to SC/IM therapy over the course of 12 months.
- Develop a robust disease management program with input from physicians and patients.
- Construct a pharmacy based MS patient facing interactive portal.
- Integrate analytic and programmatic approaches to support patient adherence.
- · Adherence metrics of this study were:
- 1. Number of missed doses in 4 weeks
- 2. Reason dose was missed
- 3. Perceived side effects
- 4. Ease of administration
- 5. Medication satisfaction
 - leoication satisfaction


Results

97.4% of all SC/IM therapy doses for participating in CareMed's and CoPilot's disease management program were administered based on physician treatment plans compared to 70.8% of all SC/IM therapy doses for patients not participating in a disease management program.

Non-Compliance Analysis N=43 Patients

Results N=1647 Patients





Work Cited

 Consortium of Multiple Sclerosis Centers 2015 Annual Meeting.

- MS Treatment Adherence Questionnaire.
- Oral Ms Drugs May Not Automatically Boost Adherence June 2015. http://www.medpagetoday.com/ MeetingCoverage/CMSC/51882.
- ES Data 2015 5. Truven Health Analytics Marketscan Meeting.



Pharmacy led MS focused disease management programs can support better adherence resulting in fewer ER visits and a reduction in overall medical costs. Further study regarding disease management programs and their impact on outcomes and costs is recommended.